// App-Quantinova.ai

OP0171 (2021) : PHASE 3 TRIAL OF LENABASUM, A CB2 AGONIST, FOR THE TREATMENT OF DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS (DCSSC)

Researchers

Presenter

  • R. Spiera

Principal Investigators

  • M. Kuwana

  • D. Khanna

  • L. Hummers

  • T. Frech

  • W. Stevens

  • J. Gordon

  • S. Kafaja

  • M. Matucci-Cerinic

  • O. Distler

  • E. B. Lee

  • Y. Levy

  • J. B. Jun

  • S. Constantine

  • N. Dgetluck

  • B. White

  • D. Furst

  • C. Denton

Medical Centers

  • Hospital for Special Surgery Main Hospital, New York, United States of America

  • Nippon Medical School Graduate School of Medicine, Department of Allergy and Rheumatology, Tokyo, Japan

  • University of Michigan School of Medicine, Ann Arbor, United States of America

  • John Hopkins University School of Medicine, Division of Rheumatology, Baltimore, United States of America

  • University of Texas, Division of Rheumatology, Dallas, United States of America

  • St Vincent's Hospital Department of Nephrology Melbourne Australia

  • Hospital for Special Surgery Main Hospital, New York, United States of America

  • David Geffen School of Medicine, University of California, Los Angeles, Division of Rheumatology, Los Angeles, California, United States of America

  • University of Florence, Department of Experimental Rheumatology, Florence, Italy

  • University Hospital Zurich, Department of Neuropathology, Zurich, Switzerland

  • Seoul National University Hospital, Division of Rheumatology, Seoul, Korea, Rep. of (South Korea)

  • Israel Sackler School of Medicine, Tel Aviv University, Department of Internal Medicine, Tel Aviv, Israel

  • Hanyang University Hospital for Rheumatic Diseases, Department of Rheumatology, Seoul, Korea, Republic of (South Korea)

  • University College London, Division of Medicine, London, United Kingdom

Locations

  • United States

  • Japan

  • Australia

  • Italy

  • Switzerland

  • Republic of South Korea

  • Israel

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Central Nervous System (CNS)

  • Autoimmune (AI)

  • Genetic Disorder

Disease

  • Scleroderma

  • Mental retardation, X-linked, syndromic, 15

Biomarkers

  • Albumin/creatinine

Drug/Treatment

  • Ajulemic acid

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

Phase

  • III

Study Id's

  • N/A

Sponsors

  • Corbus Pharmaceuticals

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved